213 related articles for article (PubMed ID: 11825447)
21. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
23. Cell proliferation of transitional cell bladder cancer determined by PCNA/cyclin immunostaining. A histopathological description.
Lipponen PK; Eskelinen MJ
Anticancer Res; 1992; 12(2):577-83. PubMed ID: 1349799
[TBL] [Abstract][Full Text] [Related]
24. [The detection of protein expression of clusterin and Ki-67 and the status of cell apoptosis in bladder transitional cell carcinoma].
Chen W; Xie D; Luo JH; Wang CX; Tao Y; Zheng KL; Mei H
Zhonghua Wai Ke Za Zhi; 2006 Jan; 44(2):111-4. PubMed ID: 16620672
[TBL] [Abstract][Full Text] [Related]
25. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
26. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins.
Chern HD; Becich MJ; Persad RA; Romkes M; Smith P; Collins C; Li YH; Branch RA
J Urol; 1996 Nov; 156(5):1846-9. PubMed ID: 8863629
[TBL] [Abstract][Full Text] [Related]
27. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
[TBL] [Abstract][Full Text] [Related]
28. [Significance of cancer cell growth and apoptosis in morphogenesis of colorectal cancer].
Seki H
Hokkaido Igaku Zasshi; 2000 Sep; 75(5):325-34. PubMed ID: 11070793
[TBL] [Abstract][Full Text] [Related]
29. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
[TBL] [Abstract][Full Text] [Related]
30. PCNA immunostaining as a valid alternative to tritiated thymidine-autoradiography to detect proliferative cell fraction in transitional cell bladder carcinomas.
Lavezzi AM; Terni L; Matturri L
In Vivo; 2000; 14(3):447-51. PubMed ID: 10904880
[TBL] [Abstract][Full Text] [Related]
31. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
[TBL] [Abstract][Full Text] [Related]
33. Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma.
Sun YW; Xuan Q; Shu QA; Wu SS; Chen H; Xiao J; Xiang P; Zhu YP; Wang FL; Zhao ST
Genet Mol Res; 2013 Apr; 12(2):1045-53. PubMed ID: 23613251
[TBL] [Abstract][Full Text] [Related]
34. [The clinico-pathological significance of protein expression of PAK1 in bladder transitional cell carcinoma].
Zhang YH; Xie D; Luo JH; Chen W; Chen LW; Xu QC; Liu GY; Ma HB; Lin WQ
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2710-3. PubMed ID: 18167251
[TBL] [Abstract][Full Text] [Related]
35. [The proliferating nuclear fraction as a prognostic factor in superficial bladder carcinomas].
Belloso L; Zugasti A; Urkia M; Arozena F; Blasco-Olaetxea E
Arch Esp Urol; 1997 Oct; 50(8):831-6. PubMed ID: 9463280
[TBL] [Abstract][Full Text] [Related]
36. [Expression of cyclooxygenase-2 in bladder transitional cell carcinoma and the significance thereof].
Yu L; Chen XJ; Shi PQ; Ding Q; Sun CH; Liu GB; Shi DM; Huang YG
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(38):2683-4. PubMed ID: 19080686
[TBL] [Abstract][Full Text] [Related]
37. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
38. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
[TBL] [Abstract][Full Text] [Related]
39. 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder.
Waldman FM; Carroll PR; Cohen MB; Kerschmann R; Chew K; Mayall BH
Mod Pathol; 1993 Jan; 6(1):20-4. PubMed ID: 8093979
[TBL] [Abstract][Full Text] [Related]
40. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
